Nimobrain (Nimodipine)

Nimodipine blocks L‑type calcium channels in the smooth muscle of cerebral arteries. This action prevents calcium‑driven contraction, causing the vessels to relax and dilate, which improves blood flow to the brain and diminishes the chance of vasospasm.

The exact dose of Nimobrain is determined by the prescribing clinician based on the patient’s condition, age, weight, and renal or hepatic function. Standard regimens are individualized, and patients should follow the prescriber’s instructions without deviation.

Pregnancy safety data for nimodipine are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit outweighs any possible risk to the fetus. Breastfeeding mothers should consult a healthcare professional before use.

To order Nimobrain, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nimobrain (nimodipine) is a selective cerebral vasodilator, whereas many other calcium channel blockers affect systemic vessels. This selectivity makes nimodipine particularly effective for preventing brain‑specific vasospasm after subarachnoid hemorrhage, while having a lower impact on overall blood pressure compared with non‑selective agents.

Nimobrain should be stored at room temperature, below 25 °C, in its original packaging. Protect the tablets from moisture and direct sunlight to maintain stability throughout its shelf life.

Nimobrain is taken orally, usually as a tablet, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

The most serious risks include severe hypotension, which can cause dizziness or fainting, and rare but serious hepatic dysfunction or allergic reactions such as rash or anaphylaxis. Patients should seek immediate medical attention if they experience sudden weakness, jaundice, or signs of a severe allergic response.

Nimobrain should be avoided in patients with known hypersensitivity to nimodipine or any component of the formulation, in those with severe liver impairment, and in individuals taking strong CYP3A4 inhibitors without appropriate dose adjustment. Clinicians should also exercise caution in patients with uncontrolled hypotension.